Richard Schumacher - Pressure Biosciences CEO
| PBIODelisted Stock | USD 0.49 0.00 0.00% |
CEO
Mr. Richard T. Schumacher is Director of the Company. He is no longer President, Chief Executive Officer, Treasurer, Secretary, Clerk of Pressure BioSciences, Inc., effective September 9, 2019. He is the founder of the Company, and has served as a director of the Company since 1978. He has served as the Companys Chief Executive Officer since April 16, 2004 and President since September 14, 2004. He previously served as Chief Executive Officer and Chairman of the Board of the Company from 1992 to February 2003. From July 9, 2003 until April 14, 2004 he served as a consultant to the Company pursuant to a consulting agreement. He served as President of the Company from August 1978 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New Englandbased medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was a research scientist and clinical laboratory director at the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School since 2017.
| Age | 73 |
| Tenure | 7 years |
| Phone | 508 230 1828 |
| Web | https://www.pressurebiosciences.com |
Pressure Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.9258) % which means that it has lost $0.9258 on every $100 spent on assets. This is way below average. Pressure Biosciences' management efficiency ratios could be used to measure how well Pressure Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Pressure Biosciences currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 2.04, implying the company greatly relies on financing operations through barrowing. Pressure Biosciences has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pressure Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Pressure Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pressure Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pressure to invest in growth at high rates of return. When we think about Pressure Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | CEO Age | ||
| Michael Brigham | ImmuCell | 63 | |
| Richard Kirk | Pro Dex | 63 | |
Management Performance
| Return On Asset | -0.93 |
Pressure Biosciences Leadership Team
Elected by the shareholders, the Pressure Biosciences' board of directors comprises two types of representatives: Pressure Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pressure. The board's role is to monitor Pressure Biosciences' management team and ensure that shareholders' interests are well served. Pressure Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pressure Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Schumacher, Founder, CEO and President Acting CFO, Treasurer, Secretary, Clerk and Director | ||
| ScD Ting, VP Engineering | ||
| Alexander Lazarev, Chief Officer | ||
| John Hollister, Director Marketing |
Pressure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Pressure Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.93 | ||||
| Operating Margin | (3.18) % | ||||
| Current Valuation | 33.23 M | ||||
| Shares Outstanding | 11.07 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 0.05 % | ||||
| Number Of Shares Shorted | 6.34 K | ||||
| Price To Earning | (1.05) X | ||||
| Price To Sales | 9.95 X | ||||
| Revenue | 2 M |
Pair Trading with Pressure Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pressure Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pressure Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Pressure OTC Stock
Moving against Pressure OTC Stock
| 0.9 | NXL | Nexalin Technology | PairCorr |
| 0.88 | PEN | Penumbra | PairCorr |
| 0.87 | VREX | Varex Imaging Corp | PairCorr |
| 0.87 | GMED | Globus Medical | PairCorr |
| 0.85 | ECOR | Electrocore LLC | PairCorr |
The ability to find closely correlated positions to Pressure Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pressure Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pressure Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pressure Biosciences to buy it.
The correlation of Pressure Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pressure Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pressure Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pressure Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Pressure OTC Stock
If you are still planning to invest in Pressure Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pressure Biosciences' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |